Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse

Maurice, Pascal; Pires, Viviane Silva; Amant, Carole; Kauskot, Alexandre; Nascimento, Sophie Da; Sonnet, Pascal; Rochette, Jacques; Legrand, Chantal; Fauvel-Lafève, Françoise; Bonnefoy, Arnaud

doi:10.1016/j.vph.2005.09.006

Cited by 18 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[33][34][35][36] These studies, like most in the field of thrombosis research, have used photochemical activation or laser irradiation to elicit and quantify thrombus development in specific regions of microscopic or macroscopic blood vessels. 37 Although these approaches have not been previously used to monitor thrombus development in the inflamed colon, there are several studies using histopathologic or electron microscopic methods that have revealed changes in the colonic microvasculature that are consistent with enhanced thrombogenesis.…”

Section: Discussionmentioning

confidence: 99%

IL-6 Mediates the Intestinal Microvascular Thrombosis Associated with Experimental Colitis

Hozumi

Russell

Vital

et al. 2016

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Inflammatory bowel diseases are associated with increased risk for thrombus formation both within the inflamed bowel and at distant sites. Although the increased propensity for distant organ thrombus development has been recapitulated in animal models of colitis and linked to interleukin-6 (IL-6), it remains unclear whether experimental colitis results in accelerated thrombus development within the inflamed bowel and whether IL-6 contributes to a local thrombogenic response. These issues related to thrombus formation within the inflamed bowel were addressed in mice with dextran sodium sulfate-induced colitis. Wild-type (WT) mice, IL-6 deficient (IL-6(-/-)) mice, and bone marrow chimeras (WT→WT and IL-6(-/-)→WT) were used. The effects of treatment with either an IL-6-blocking, IL-6Rα-blocking or gp130-blocking antibody were also evaluated. Disease activity index and colonic weight-to-length ratio (W/L) were used to monitor the development of colitis. Intravital videomicroscopy was used to study thrombus development (induced with the light/dye method) in mucosal vessels of the ascending colon. Thrombus development was significantly enhanced in WT colitic mice. Neither genetic deficiency nor immunoblockade of IL-6 significantly altered the disease activity index and W/L responses to dextran sodium sulfate treatment. However, colitis-induced thrombogenesis was attenuated in IL-6(-/-) mice and in WT mice treated with either the IL-6-blocking, IL-6Rα-blocking or gp130-blocking antibody. IL-6(-/-)→WT, but not WT→WT chimeras, exhibited a blunted thrombosis response to dextran sodium sulfate. These results indicate that experimental colitis is associated with accelerated thrombus development within the inflamed colon and that IL-6, derived from bone marrow-derived blood cells, is largely responsible for this response.

show abstract

Section: Discussionmentioning

confidence: 99%

IL-6 Mediates the Intestinal Microvascular Thrombosis Associated with Experimental Colitis

Hozumi

Russell

Vital

et al. 2016

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…In another work, the effect of type III collagen-related octapeptide KOGEOGPK (where O is hydrolyproline) on the in vitro prevention of mouse platelet interaction/adhesion with sub-endothelial type III collagen was investigated. The administration of 80 mg/kg of KOGEOGPK reduced the induced-thrombi in mouse by 50% and could decrease the occurrence of arteriole occlusion by 76% 45 min after injection (Maurice et al 2006). This interaction/adhesion is a normal hemostatis such as in the event of vascular injury, but can also contribute to the underlying pathologies associated with enhanced thrombosis such as myocardial infarction, stroke, unstable angina, and ischemia (Weiss, 1975a, b).…”

Section: Anti-thrombotic Peptidesmentioning

confidence: 99%

Chapter 4: Literature review

Angel¹,

Bjerregaard²,

O’Connor³

et al. 2015

Journal of Wound Care

View full text Add to dashboard Cite

“…We have previously reported that the peptide 1 inhibits type III collagen-induced human platelet aggregation [8]. Herein, the peptides 1-4 are tested (in triplicates at least) on the human platelets, platelet aggregation being induced by 10 mg/mL of human type III collagen.…”

Section: Platelet Aggregation Assaymentioning

confidence: 99%

“…This octapeptide 1 inhibits platelet interaction with type III collagen in both static and flow conditions [6,7]. In vivo, the octapeptide 1 prevents photochemically-induced thrombosis in arterioles of mice without affecting bleeding time [8].…”

Section: Introductionmentioning

confidence: 99%

Circular dichroism studies of type III collagen mimetic peptides with anti- or pro-aggregant activities on human platelets

Pêcher

Pires

Djaafri

et al. 2009

European Journal of Medicinal Chemistry

Self Cite

View full text Add to dashboard Cite

Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse

Cited by 18 publications

References 28 publications

IL-6 Mediates the Intestinal Microvascular Thrombosis Associated with Experimental Colitis

IL-6 Mediates the Intestinal Microvascular Thrombosis Associated with Experimental Colitis

Chapter 4: Literature review

Circular dichroism studies of type III collagen mimetic peptides with anti- or pro-aggregant activities on human platelets

Contact Info

Product

Resources

About